Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Adeno-Associated Viral Vectors Market Size Shifted, And What Is the Outlook Through 2034?
The market size for adeno-associated viral vectors has seen swift growth in recent years. It is projected to rise from $2.69 billion in 2024 to $3.17 billion in 2025, showcasing a compound annual growth rate (CAGR) of 17.6%. The historic growth can be credited to vaccine research, amplified funding and investments, collaborations between academia and industry, clinical trial expansions, and increased public awareness and advocacy.
The market size of the adeno-associated viral vectors is anticipated to witness rapid expansion in the approaching years. It’s projected to reach $5.85 billion by 2029, expanding at a compound annual growth rate (CAGR) of 16.6%. This growth during the predicted period is due to various factors such as the broadening of therapeutic uses, an increase in genetic and neurological disorders, regulatory backing and approvals, and decreased production costs. Key developments expected in the forecast length include progress in gene therapy, innovative technology, scalable manufacturing procedures, collaborations, investments, and technological advancements.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Adeno-Associated Viral Vectors Market?
The adeno-associated viral vectors market is predicted to expand due to the growing occurrence of genetic disorders. These disorders are abnormalities in an individual’s DNA, which could lead to physical or developmental deformities. The emergence of advanced diagnostic methods, increased awareness, elevated reproductive age, environmental factors, and genetic drift contribute to the escalating prevalence of these genetic disorders. Adeno-associated viral vectors play a crucial role in gene therapy for genetic disorders, introducing corrective genes into cells to potentially address conditions such as muscular dystrophy or cystic fibrosis. In February 2023, the World Health Organization (WHO), a Swiss-based UN agency dedicated to global public health, revealed that congenital diseases were responsible for an approximate 240,000 infant deaths worldwide within the first 28 days after birth each year. In addition, congenital diseases cause the death of an extra 170,000 kids aged between 1 month and 5 years. As such, the escalating occurrence of genetic disorders is fueling the growth of the adeno-associated viral vectors market.
Which Primary Segments of the Adeno-Associated Viral Vectors Market Are Driving Growth and Industry Transformations?
The adeno-associated viral vectorsmarket covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation; Immunotherapy; Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo; In Vivo
3) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical; Clinical; Commercial
5) By Application Area: Gene Therapy; Cell Therapy; Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders; Muscular Dystrophy; Cystic Fibrosis; Hemophilia
2) By Immunotherapy: Cancer Immunotherapy; Viral Infections Immunotherapy; Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing; RNA Therapy; Antiviral Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Adeno-Associated Viral Vectors Market?# Market?
North America was the largest region in the adeno-associated viral vectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Adeno-Associated Viral Vectors Market?
Major firms in the adeno-associated viral vectors market, such as Charles River Laboratories International Inc., are distinguishing themselves by providing ready access to replication-capsid plasmid. Rep/Cap plasmids are often used in gene therapy for adeno-associated virus (AAV) vector production and are readily accessible from many commercial suppliers that serve the molecular biology research needs. For example, in January 2024, this US-based pharmaceutical company launched a range of off-the-shelf replication-capsid plasmids aiming to streamline AAV-based gene therapy efforts. This addition to their product line complements their current lentiviral packaging and AAV Helper plasmid offerings and potentially reduces manufacturing efforts by up to 66%. These prepared plasmids undergo a detailed batch production process and are accompanied by documentation, adhering to CMC guidelines and a Certificate of Analysis (COA) to aid IND and Clinical Trial Application (CTA) submissions.
View the full report here:
What Parameters Are Used to Define the Adeno-Associated Viral Vectors Market?
Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses commonly used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. AAV’s safety profile and ability to efficiently infect both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model